Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Hiatt R, Ordonez JD 1994 USA | 20981 patients (men aged>35 years and women aged>55 years) selected by a computer-stored file. All had a Personal Health Appraisal from a prepaid health plan in 1980. After exclusions for possible existing conditions which might cause haematuria patients were dipsticked and the two patient groups remaining were 19875 (no haematuria) and 598 (asymptomatic microscopic haematuria) | Retrospective cohort study | Number of serious outcomes (urinary tract cancers) discovered in the following 3 years in patient group with AMH (predictive value of a single specimen with microhaematuria) | 3 (0.5%) | Only one single dipstick test used to detect AMH. Some demographic groups not included. |
Number of serious outcomes (urinary tract cancers) discovered in the following 3 years in patient group with no haematuria | 102 (0.5%) | ||||
For indicating urological cancers | Sensitivity of AMH = 2.9% | ||||
Specificity of AMH = 96.7% | |||||
Yasumasu et al 1994 Japan | 355 patients (135 men, 220 women) with AMH visiting hospital between Jan 1986 and Dec 1990 | Retrospective cohort study | Number of urologic abnormalities on investigation | 69 (19.4%) including 1 malignancy (0.3%) | Included patients under 18 years of age (16 in total). Patients were included regardless of proteinuria, pyuria and/or bacteruria accompanying their hameaturia. Definition of degree of haematuria required for inclusion in the study not stated. |
Rate of urologic abnormalities in subjects under 40 years | 7/54 (13%) | ||||
Rate of urologic abnormalities in subjects over 40 years | 62/301 (20.6%) including 1 malignancy | ||||
Khadra et al 2000 UK | 1930 pateints enrolled from a hematuria clinic between Oct 1994 and March 1997. 1194 males, 736 females, mean age 58 years (range 17 - 96). Number of patients with microscopic haematuria 982. | Prospective study | Proportion of patients with AMH found to have significant disease | 18.7% | Includes subjects under 18 years of age. Definition of 'significant disease' not stated |
Total rate of cancer found in patients with AMH | 51/982 (5.2%) | ||||
Rate of cancer found in subjects with AMH under 40 years | 1/143 (0.7%) | ||||
Rate of cancer found in subjects with AMH greater than 40 years | 50/839 (6%) | ||||
Suzuki et al 1999 Japan | 263 patients (83 males, 180 females) between Jan 1993 and March 1996 showing haematuira on dipstick on annual health screening examination. Average age was 54.7 (range 16-92) 79 patients were younger than 40 years. | Prospective cohort study | Highly significant lesions (likely to be a threat to life without immediate treatment) detected on evaluation | 18 (6.8%) (including 8 bladder cancers (3%) where all subjects were greater than 40 years of age) | Sensitivities and specificities not recorded for any outcome other than bladder cancer. Only microscopic haematuria included. |
Moderately significant (no threat to life, but where haematuria was expected to resolve with treatment) lesions detected on evaluation | 52 (19.8%) | ||||
Murakami et al 1990 Japan | 1034 adults with asymptomatic microhaematuria noted after annual health checks. Average patient age 53.4 years. Male:female ratio approx. 1:3. | Prospective cohort study | highly significant lesions detected | 30 (2.9%) consisting of 24 malignancies and 6 glomerulopathic conditions that may progress to renal failure | No breakdown of incidence in different demographic groups except a statement that all bladder cancers were in over 40 year olds. Predominance of women in this study may be significant since the findings showed a higher incidence of significant lesions in the men |
moderately significant lesions | 195 (18.9%) | ||||
Sugimura et al 2001 Japan | 823 asymptomatic adults with microhaematuria presenting between May 1993 and Nov 1998. | Retrospective cohort study | Positive predictive value of AMH for bladder carcinoma | 1.7% (14 cases) | Due to retrospective nature of study the diagnostic process for each patient depended on the decision of the particular urologist in charge of the patient. Full results not broken down according to demographics (age, gender) |
Positive predictive value of AMH for ureteral/renal pelvic carcinoma | 0.4% (3 cases) | ||||
Positive predictive value of AMH for renal cell carcinoma | 0.2% (2 cases) | ||||
Total PPV of AMH for urological cancers | 2.9% (since 5 cases of prostate cancer were diagnosed incidentally) | ||||
If results are limited to men aged over 50 years, PPV for urothelial carcinomas and for total urologic cancers | 6.2% (14/225) and 9.3% respectively |